ARG62738
anti-CD158d / KIR2DL4 antibody [mAb#33]
anti-CD158d / KIR2DL4 antibody [mAb#33] for Flow cytometry,Functional study,ICC/IF,Immunoprecipitation,Western blot and Human
Immune System antibody
Overview
| Product Description | Mouse Monoclonal antibody [mAb#33] recognizes CD158d / KIR2DL4 |
|---|---|
| Tested Reactivity | Hu |
| Tested Application | FACS, FuncSt, ICC/IF, IP, WB |
| Specificity | The clone mAb 33 (also known as mAb 33 or 33) recognizes extracellular portion of CD158d / KIR2DL4, a 45 kDa NK cell marker. Cell surface expression and function of CD158d / KIR2DL4 depends on genotype of particular individuals. |
| Host | Mouse |
| Clonality | Monoclonal |
| Clone | mAb#33 |
| Isotype | IgG1 |
| Target Name | CD158d / KIR2DL4 |
| Immunogen | NK3.3 cells and KIR2DL4-Ig fusion protein |
| Conjugation | Un-conjugated |
| Alternate Names | KIR103; CD158 antigen-like family member D; Killer cell immunoglobulin-like receptor 2DL4; CD158D; CD antigen CD158d; G9P; Killer cell inhibitory receptor 103AS; KIR-103AS; KIR103AS; MHC class I NK cell receptor KIR103AS |
Application Instructions
| Application Suggestion |
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application Note | Functional studies: Cytokine secretion studies. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. |
Properties
| Form | Liquid |
|---|---|
| Purification | Purified from cell culture supernatant by protein-A affinity chromatography. |
| Purity | > 95% (by SDS-PAGE) |
| Buffer | PBS (pH 7.4) and 15 mM Sodium azide |
| Preservative | 15 mM Sodium azide |
| Concentration | 1 mg/ml |
| Storage Instruction | For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. |
| Note | For laboratory research only, not for drug, diagnostic or other use. |
Bioinformation
| Database Links |
Swiss-port # Q99706 Human Killer cell immunoglobulin-like receptor 2DL4 |
|---|---|
| Gene Symbol | KIR2DL4 |
| Gene Full Name | killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 |
| Background | CD158d / KIR2DL4 is a KIR family member that shares structural features with both activating and inhibitory receptors and may mediate different functions under different circumstances. It contains cytoplasmic ITIM, suggesting inhibitory function, but also transmembrane domain similar to those of activating KIRs. It has been reported that CD158d serves as an inhibitory receptor for peripheral and uterine NK cells, but its ligation with soluble mAbs (unlike immobilized mAbs) results in activation of IFN-γ secretion. CD158d also binds both membrane form and soluble form of its ligand HLA-G. |
| Function | Receptor on natural killer (NK) cells for HLA-C alleles. Inhibits the activity of NK cells thus preventing cell lysis. [UniProt] |
| Research Area | Immune System antibody |
| Calculated MW | 41 kDa |
Images (1) Click the Picture to Zoom In
-
ARG62738 anti-CD158d / KIR2DL4 antibody [mAb#33] FACS image
Flow Cytometry: Human lymphocytes stained with ARG62738 anti-CD158d / KIR2DL4 antibody [mAb#33] at 6 µg/ml dilution, followed by APC-conjugated Goat anti-Mouse antibody. Cells were co-stained with anti-CD56 antibody [LT56] (PE) at 1 µg/ml dilution.
Clone References
Soluble human leukocyte antigen-g5 activates extracellular signal-regulated protein kinase signaling and stimulates trophoblast invasion.
WB / Human
Activation of NK cells by an endocytosed receptor for soluble HLA-G.
HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells.
KIR2DL4 (CD158d) genotype influences expression and function in NK cells.
Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells.
